© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I study of MEDI3617 for advanced solid tumors.
David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I study of MEDI3617 for advanced solid tumors.